Xpel

XPEL · NASDAQ

$45.16+$1.03 (+2.33%)TodayMarket closed ·
Prev close $44.13

XPEL analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy2
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 5 analysts

Average $62.90 (+39.3% upside)

Low
$60.60
Now
$45.16
High
$68.25

Upgrades and downgrades

The latest rating actions, newest first

XPEL analyst upgrades, downgrades and rating actions
FirmDateActionRating
Freedom BrokerAug 7, 2026UpgradeHold → Buy
B. Riley SecuritiesAug 6, 2026MaintainsBuy
Freedom BrokerNov 7, 2025MaintainsBuy

The case for and against

Updated May 8, 2024

Bull case

XPEL is showing strong growth in both its architectural film and fusion ceramic coating sales, with these segments collectively accounting for nearly 15% of total revenue. In addition, the company's acquisition of a European-based installation business and increasing contribution from China are expected to drive revenue growth in the near future. Despite lower sales in the Canadian market, XPEL's overall AEBITDA margin increased and the company continues to expand its international business and secure new OEM relationships, signaling a positive outlook for the company's future financial performance.

Bear case

XPEL is facing challenges such as a weaker macroeconomic environment affecting consumer spending, potential input cost increases, and difficulties in entering new geographic markets. This could result in lower-than-expected growth and profitability for the company. Analysts have lowered their estimates and price target for the stock in anticipation of these challenges.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.